mRNA Skin Cancer Vaccine Shown to Significantly Cut Recurrence Risk, Expanding Case for Personalized Cancer Immunotherapy

Skin cancer patients could soon benefit from an mRNA-based personalized cancer vaccine shown to significantly reduce recurrence risk, advancing the clinical case for individualized cancer immunotherapy beyond the melanoma trials already underway. The findings build on the Moderna/Merck mRNA-4157/V940 neoantigen vaccine program, which demonstrated a ~49% reduction in recurrence or death versus pembrolizumab alone in resected high-risk melanoma (Phase 2b KEYNOTE-942), and extend the therapeutic promise to broader skin cancer populations. Personalized mRNA cancer vaccines work by encoding a patient's unique tumor neoantigens, priming the immune system to target residual cancer cells. With Phase 3 melanoma trials underway and readouts expected in 2026–2027, this development reinforces momentum for mRNA's role as a precision oncology platform.